Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

PILA PHARMA AB (5KC) Stock Price & Analysis

0 Followers

5KC Stock Chart & Stats

€0.13-€0.01(3.10%)
At close: 5:30 PM GMT+1
€0.25€0.5Dec 19Aug 5Jan 15Jul 28Feb 18
Day’s Range
EUR 0.13 - EUR 0.14
52-Week Range
EUR 0.09 - EUR 0.21
Previous Close
EUR 0.13
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 6.59M
Enterprise Value
EUR 42.98M
Total Cash (Recent Filing)
EUR 3.26M
Total Debt (Recent Filing)
EUR 0
Price to Earnings (P/E)
―
Beta
0.11
Next Earnings
Feb 25, 2027 (Est.)
EPS Estimate
-0
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Focused Drug-development Strategy

A focused development strategy can concentrate scarce resources and scientific effort on a large, clearly defined disease area. PILA’s emphasis on type 2 diabetes and a single lead program may support coherent execution and create meaningful value if clinical development succeeds.

Low Financial Leverage

Zero reported debt reduces fixed financial obligations and near-term balance-sheet pressure while the company remains pre-commercial and loss-making. This gives management more flexibility than a highly leveraged structure, although future funding needs still depend on development progress.

Oral Therapeutic Platform

An oral small-molecule approach is aligned with the stated goal of improving glucose control and provides a clearly defined product format for development. If efficacy and safety are demonstrated, this candidate could form the basis for partnering or future commercialization.

Bears Say

Severe Revenue Deterioration

Sharp revenue deterioration leaves PILA with limited demonstrated commercial traction and weak operating leverage. Because the company is pre-commercial, continued low or falling revenue increases dependence on successful clinical progress and makes it harder to fund development through internally generated business.

Deep And Persistent Losses

Deep losses indicate that current operations do not yet support the cost of development and provide no evidence of sustainable profitability. Continued negative margins can consume equity over time, constrain strategic choices, and increase the financing required before a product reaches commercialization.

Persistent Cash Burn

Persistent negative operating and free cash flow means PILA cannot currently fund its activities from internal cash generation. The worsening TTM burn versus 2025 reinforces reliance on external funding and raises the risk of future capital needs or shareholder dilution.

5KC FAQ

What was PILA PHARMA AB’s price range in the past 12 months?
PILA PHARMA AB lowest stock price was €0.09 and its highest was €0.21 in the past 12 months.
What is PILA PHARMA AB’s market cap?
PILA PHARMA AB’s market cap is €6.59M.
When is PILA PHARMA AB’s upcoming earnings report date?
PILA PHARMA AB’s next earnings report is estimated for Feb 25, 2027 (not yet confirmed), which is in 105 days.
How were PILA PHARMA AB’s earnings last quarter?
PILA PHARMA AB released its earnings results on Aug 27, 2026. The company reported -€0.007 earnings per share for the quarter, beating the consensus estimate of -€0.02 by €0.013.
Is PILA PHARMA AB overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does PILA PHARMA AB pay dividends?
PILA PHARMA AB does not currently pay dividends.
What is PILA PHARMA AB’s EPS estimate?
PILA PHARMA AB’s EPS estimate is -0.00.
How many shares outstanding does PILA PHARMA AB have?
PILA PHARMA AB has 45,682,120 shares outstanding.
What happened to PILA PHARMA AB’s price movement after its last earnings report?
PILA PHARMA AB reported an EPS of -€0.007 in its last earnings report, beating expectations of -€0.02. Following the earnings report the stock price went down -7.971%.
Which hedge fund is a major shareholder of PILA PHARMA AB?
Currently, no hedge funds are holding shares in DE:5KC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology